

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number  
**WO 2005/082344 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/136**

(21) International Application Number:  
PCT/US2005/005754

(22) International Filing Date: 23 February 2005 (23.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/547,130 24 February 2004 (24.02.2004) US

(71) Applicant (for all designated States except US):  
**SMITHKLINE BEECHAM CORPORATION**  
[US/US]: One Franklin Place, P.O. Box 7929, Philadelphia, Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOODWIN, Bryan, James** [GB/US]: GlaxoSmithKline, Five Moore Drive, Post Office Box 13398, Research Triangle Park, North Carolina 27709 (US); **STEWART, Eugene, Lee** [US/US]: GlaxoSmithKline, Five Moore Drive, Post

Office Box 13398, Research Triangle Park, North Carolina 27709 (US); **BROWN, Peter, Jonathan** [GB/US]: GlaxoSmithKline, Five Moore Drive, Post Office Box 13398, Research Triangle Park, North Carolina 27709 (US); **DELERIVE, Philippe** [FR/FR]: GlaxoSmithKline, Centre de Recherches, Z.A. de Courtabœuf, 25 Avenue du Quebec, F-91940 Les Ulis (FR).


(74) Agents: **DADSWELL, Charles, E.** et al.; GlaxoSmithKline, Five Moore Drive, Post Office Box 13398, Research Triangle Park, North Carolina 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

**4 Title:** LRH1 ACTIVATORS AS MEDICAMENTS



: Methods or prevention or treatment of diseases or conditions caused by low plasma apoA-I levels, the use of LRH1 ch methods and methods for the identification of compounds useful in such treatment.